Head of Finance at Remix Therapeutics

Watertown, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

10+ years of progressive finance and accounting experience, including senior leadership roles
Proven track record in a private life sciences/biotech company with both clinical and pre-clinical programs
Strong understanding of GAAP and biotech-specific accounting issues, including R&D accruals and clinical trial accounting
Experience managing direct reports and external vendors
Demonstrated ability to work independently in a fast-paced, entrepreneurial environment
CPA or MBA strongly preferred
Experience supporting fundraising activities (venture capital, crossover, IPO readiness) preferred
Familiarity with cost modeling for clinical development and pre-clinical programs preferred

Responsibilities

Serve as the company’s controller, overseeing all accounting operations, financial reporting, and internal controls
Ensure compliance with GAAP and all applicable regulations
Manage monthly, quarterly, and annual close processes, as well as audit, tax, and regulatory filings
Partner with the CBO/COO and leadership team to develop and refine the company’s financial strategy and long-term operating plan
Provide scenario modeling, budget forecasts, and capital allocation recommendations
Support fundraising activities, investor relations, and board-level financial reporting
Implement and maintain scalable accounting and financial systems, processes, and tools
Oversee cash flow management, including tracking of R&D expenses, clinical trial budgets, and operational spend
Manage and mentor a small internal finance team, fostering growth and accountability
Oversee and coordinate work of external vendors, including auditors, accounting consultants, tax advisors, and payroll providers
Ensure vendors meet performance expectations, budgets, and timelines

Skills

GAAP

Financial Reporting

Internal Controls

Accounting Operations

Financial Modeling

Budget Forecasting

Scenario Modeling

Capital Allocation

Audit Management

Tax Filings

Regulatory Compliance

Controller Experience

Remix Therapeutics

Develops mRNA-based treatments for rare diseases

About Remix Therapeutics

Remix Therapeutics focuses on creating treatments for rare and difficult diseases, particularly targeting rare cancers and genetic disorders. Their main product, REM 422, is an oral small molecule that works by degrading messenger RNA (mRNA), which can stop the production of harmful proteins linked to these diseases. Currently, REM 422 is undergoing Phase 1 clinical trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, and it has received Orphan Drug Designation from the FDA, which offers benefits for drugs treating rare conditions. Unlike many competitors, Remix Therapeutics emphasizes a strong research and development approach, funding their work through grants and partnerships, with the goal of bringing new medicines to patients inspired by personal experiences with serious illnesses.

Cambridge, MassachusettsHeadquarters

2018Year Founded

$205.2MTotal Funding

GROWTH_EQUITY_VCCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees